BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 15, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ADL5945: Phase II data

Top-line data from the double-blind, U.S. Phase II Study 243 trial in 81 chronic non-cancer pain patients with OIC showed that once-daily 0.25 mg ADL5945 met the primary endpoint of significantly increasing the weekly average number of SBMs from baseline to week...

Read the full 189 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >